Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas

Ina Oehme, Marco Lodrini, Nathan R. Brady, Olaf Witt

Research output: Contribution to journalShort surveypeer-review

Abstract

Neuroblastoma is the most common extracranial solid tumor in childhood. Despite intense multimodal therapy and many improvements through basic scientific and clinical research, the successful response of advanced-stage patients to chemotherapy remains poor. Autophagy is a cytoprotective mechanism that may help advanced cancer cells survive stressful conditions such as chemotherapy. Here we review our recent findings describing HDAC10 as a promoter of autophagy-mediated survival in neuroblastoma cells and identifying this HDAC isozyme as a druggable regulator of advanced-stage tumor cell survival. These results propose a new and promising way to considerably improve treatment response in the neuroblastoma patient subgroup with the poorest outcome.

Original languageEnglish (US)
Pages (from-to)2163-2165
Number of pages3
JournalAutophagy
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Keywords

  • Drug resistance
  • HDAC-inhibitor
  • HDAC10
  • Lysosome
  • Macroautophagy
  • Neuroblastoma

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas'. Together they form a unique fingerprint.

Cite this